STAT3 and neoplasm: The role of STAT3 in TAM as an important target for cancer immunotherapy was first described by Cheng et al. They showed that the disruption of the STAT3 pathway restored the responsiveness of immunotolerant T-cells from tumor-bearing mice [82].